Rapid Detection and Identification of Uveitis Pathogens by Qualitative Multiplex Real-Time PCR by Bispo, Paulo J. M. et al.
Rapid Detection and Identification
of Uveitis Pathogens by Qualitative
Multiplex Real-Time PCR
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Bispo, Paulo J. M., Samaneh Davoudi, Matthew L. Sahm, Ai Ren,
John Miller, John Romano, Lucia Sobrin, and Michael S. Gilmore.
2018. “Rapid Detection and Identification of Uveitis Pathogens by
Qualitative Multiplex Real-Time PCR.” Investigative Ophthalmology
& Visual Science 59 (1): 582-589. doi:10.1167/iovs.17-22597. http://
dx.doi.org/10.1167/iovs.17-22597.
Published Version doi:10.1167/iovs.17-22597
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34868827
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Immunology and Microbiology
Rapid Detection and Identification of Uveitis Pathogens by
Qualitative Multiplex Real-Time PCR
Paulo J. M. Bispo,1,2 Samaneh Davoudi,1 Matthew L. Sahm,1 Ai Ren,1 John Miller,1
John Romano,1 Lucia Sobrin,1 and Michael S. Gilmore1,2
1Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, United States
2Department of Microbiology and Immunology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston,
Massachusetts, United States
Correspondence: Michael S. Gil-
more, Massachusetts Eye and Ear
Infirmary, Harvard Medical School,
243 Charles Street, Boston, MA
02114, USA;
michael_gilmore@meei.harvard.edu.
Submitted: July 11, 2017
Accepted: December 7, 2017
Citation: Bispo PJM, Davoudi S, Sahm
ML, et al. Rapid detection and identi-
fication of uveitis pathogens by qual-
itative multiplex real-time PCR. Invest
Ophthalmol Vis Sci. 2018;59:582–
589. https://doi.org/10.1167/
iovs.17-22597
PURPOSE. Infectious uveitis is a serious sight-threatening infection commonly caused by
herpesviruses and Toxoplasma gondii. Etiologic diagnosis based on the clinical evaluation is
often challenging. We developed and validated a multiplex real-time PCR assay coupled with
high-resolution melting (HRM) for rapid detection and identification of herpes simplex viruses
1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV), cytomegalovirus (CMV), and T. gondii.
METHODS. The assay was designed to target pathogen genome regions that yield products with
distinct melting temperatures. Analytical specificity, sensitivity, and precision of HRM
identification were determined. Clinical validation was performed by testing 108 intraocular
fluids collected from eyes suffering with infectious uveitis (n ¼ 30) and controls (n ¼ 78).
RESULTS. A nonoverlapping high-precision profile for each pathogen was generated following
HRM (coefficient of variation 0%). The assay was highly sensitive, with a limit of detection of
20 genome copies for herpesviruses and 200 genome copies for T. gondii. The intra- and
interassay variability of cycle threshold (Ct) measurement was 4% and 6%, respectively.
Thirteen intraocular specimens collected from suspected cases of infectious uveitis were
positive (mean Ct values varied from 19.4 to 27.7). Melting profiles of positive cases were
consistent with HSV-2 (n ¼ 5), VZV (n ¼ 5), CMV (n ¼ 2), and T. gondii (n ¼ 1). Amplicon
identities were confirmed by sequencing. Control intraocular samples from patients without a
clinical diagnosis of infectious uveitis were all negative.
CONCLUSIONS. This assay allows rapid, sensitive, and reliable detection and identification of the
most common known causes of infectious uveitis, making early pathogen information-based
intervention possible.
Keywords: infectious uveitis, herpesviruses, toxoplasmosis, multiplex real-time PCR, high-
resolution melting
Uveitis is the inflammation of the uvea, the pigmentedvascular middle layer of the eye, which comprises the iris,
ciliary body, and choroid. In the United States, uveitis has a
prevalence of 57.5 to 115.3 cases per 100,000 person-years1,2 and
is thought to be associated with 10% of all cases of blindness.3
The etiology of uveitis is often unclear, and only approximately
17% of uveitis cases are caused by an infectious agent that is
ultimately identified.4 Toxoplasma gondii and herpesviruses,
including herpes simplex virus types 1 and 2 (HSV-1 and HSV-2),
varicella-zoster (VZV), and cytomegalovirus (CMV), are the most
common known causes of infectious uveitis, although bacteria,
fungi, and other viruses and parasites may also be involved.4–7
Diagnosis of uveitis is frequently made on the basis of the
patient’s history and findings upon clinical examination.
Ascribing an etiology is complicated by overlapping clinical
findings among cases caused by different infectious agents and
also with observations made for noninfectious causes of uveitis,
such as those caused by autoimmune diseases and trauma.4,8
This ambiguity may delay the onset of potentially effective
treatment. For example, syphilitic uveitis, atypical toxoplasmic
retinitis, fungal endophthalmitis, and noninfectious uveitis may
be misdiagnosed as viral retinitis.9,10 Furthermore, many
noninflammatory ocular disorders (neoplastic and nonneoplas-
tic) may present as intraocular inflammatory diseases (mas-
querade syndromes) and may be diagnosed and treated as
uveitis.11 For these reasons, there is considerable interest in
molecular detection of uveitis-associated pathogens directly in
intraocular fluids of suspected uveitis cases.7,9,12,13 Therefore,
our goal was to develop a rapid and sensitive diagnostic test for
the leading known causes of infectious uveitis, with the
potential to impact management of patients in a timely fashion.
To achieve this we developed a multiplex assay using real-time
PCR detection,14 coupled with high-resolution melting (HRM)
analysis of the amplification products15 to rapidly detect and
identify herpesviruses (HSV-1, HSV-2, VZV, and CMV) and T.
gondii in a single reaction. This goal was achieved with an assay
that provided both high sensitivity and specificity.
METHODS
Selection of Target Sequences and Primer Design
Conserved areas of pathogen genomes identified in herpesvi-
ruses and T. gondii from human specimens (Table 1;
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Supplementary Table S1) were scrutinized for coding stretches
that would yield PCR products with distinct, predicted melting
curve profiles. Such amplification targets were identified in
silico using the melting curve prediction software uMelt.16
Predictions were made based on thermodynamic parameters
described by Blake and Delcourt,17 assuming default concen-
trations of monovalent ions (20 mM), free magnesium (3 mM),
and a temperature step size of 0.18C over the range of 608C to
998C. The targeted regions were selected for predicted melting
temperature (Tm) values differing by at least 628C for each
organism and the greatest value for the negative derivate of
helicity with respect to temperature (d[Helicity]/d[Temp]).
This yielded theoretical PCR products with the highest
predicted melting peak in the derivative of fluorescence with
respect to temperature (dF/dT) axis in the dissociation curve.
The main variables used to optimize discrete melting profiles
were length of product and guanine-cytosine (GC) content.
After identifying theoretically optimal regions for amplification,
a set of target-specific primers was designed to uniquely
amplify VZV, CMV, and T. gondii DNA. A set of universal
primers that can amplify both HSV1 and HSV2 was also
included (Table 1). The universal HSV1/2 primers were
designed to amplify a variable region within the gene UL27
that results in distinct DNA melting profiles, allowing
differentiation of these two herpes simplex virus subtypes by
Tm. Primers were further optimized to minimize potential for
primer-dimer and hairpin formation using AutoDimer.18
Primer Validation and PCR Optimization
Purified genomic DNA from HSV1 strain MacIntyre (VR-
529DQ), HSV2 strain MS (VR-540DQ), VZV strain Ellen (VR-
1367DQ), CMV strain AD169 (VR-538DQ), and T. gondii strain
RH (ATCC 50174D), obtained from American Type Culture
Collection (ATCC; Manassas, VA, USA), were used for primer
validation and PCR optimization. To confirm the specificity and
potential cross-amplification of the designed primers, each
primer pair was first tested against all five targets. Correct
amplification was confirmed by gel electrophoresis and by
analysis of Tm values. Subsequently, the multiplex reaction was
optimized by testing different primer concentrations, ranging
from 100 to 700 nM.
Real-Time Multiplex PCR
Real-time PCR amplification and HRM analysis was performed
in 25-lL reactions containing 12.5 lL 2X Express SYBR
GreenER qPCR Supermix (ThermoFisher, Waltham, MA,
USA), 2 uL purified DNA, and sterile water to complete to
the final volume. PCR was performed using a real-time PCR
cycler system (Rotor-Gene Q5-Plex; Qiagen, Hilden, Germany)
under the following conditions: 508C initial annealing and
extension for 2 minutes, 958C denaturation for 5 minutes,
followed by 40 cycles of denaturation (958C for 5 seconds) and
annealing/extension (608C for 10 seconds). HRM analysis was
immediately performed afterward by heating samples from
708C to 998C, using a temperature ramp of 0.18C/s. Negative
controls for contamination lacked added DNA but contained all
PCR reagents and were included on each run. As an
endogenous positive reaction control, amplification of the
human b-globin gene was performed in a separate singleplex
PCR format, as previously published.19
Intra- and Interassay Variation
The intra- and interassay coefficient of variation was deter-
mined by measuring the Ct values of concentrations near or at
(200 copies per reaction) and above the limit of detection (23
104 copies per reaction). The variation in the Tm values for
pathogen identification was also determined. Precision calcu-
lations were based on the results of five technical replicate
reactions performed on each of 4 consecutive days.
Analytical Specificity and Sensitivity
In addition to testing each primer set for absence of cross-
amplification of targets in the multiplex reaction, analytical
specificity was also determined by spiking TE buffer with DNA
(10 ng/lL) from other pathogens often associated with
nonuveitis intraocular infections. These included Staphylococ-
cus epidermidis, Propionibacterium acnes, Staphylococcus
aureus, Candida albicans, Mycobacterium tuberculosis, and
Treponema pallidum.
Analytical sensitivity of the assay was evaluated using
purified control genomic (for HSV-1, HSV-2, CMV, VZV) or
plasmid (carrying the targeted T. gondii genome region) DNA
of known concentration. To clone the relevant portion of the T.
gondii genome on a plasmid for propagation in E. coli, the T.
gondii sequence of interest was amplified by PCR using high-
fidelity DNA polymerase (Q5; New England Biolabs, Ipswich,
MA, USA) cloned into the pCR4 Blunt TOPO vector (Zero Blunt
TOPO PCR Cloning Kit; ThermoFisher), and transformed into
chemically competent E. coli TOP10 (ThermoFisher). Solutions
containing known amounts of purified DNA were diluted 10-
fold in nuclease-free water to obtain final concentrations
ranging from 13 105 genome copies/lL to 1 copy/lL.
Assay Validation
Protocols for collection of discarded aqueous and undiluted
and diluted vitreous specimens were approved by the
Massachusetts Eye and Ear Institutional Review Board. All
TABLE 1. Primer Sequences Used in This Study and Characteristics of Their Respective PCR Products
Target Name Sequence Gene (Locus Tag)
Product
Size, bp
Product
%GC
Tm
Prediction*
Practical
Tm
HSV-1 HSV-2 HSV1/2Fw CATGACCAAGTGGCAGGA Glycoprotein (UL27) 235 64 (HSV1) 91.6 (HSV1) 90.3
HSV1/2Rv CAGGTAGTACTGCGGCTG 66 (HSV2) 91.9 (HSV2) 90.8
CMV CMVFw AAGGGGAAGACGCGGTAG Regulatory protein IE2 (UL122) 214 55 87.1 85.7
CMVRv ACGCGTCCTTTCAAGGTG
VZV VZVFw TCCGTTCGTTTTGGCTTC Glycoprotein B (ORF31) 223 45 83.0 81.7
VZVRv TTGGACTTTCCACGGGAG
T. gondii ToxFw AGCGTGTTCGTCTCCATT Glycerol-3-phosphate dehydrogenase 114 44 80.5 79.1
ToxRv AAGATAGGAGGGAGGCGT
Tm, melting temperature; GC, guanine-cytosine.
* The Tm for the PCR products of each target were predicted using the melting curve prediction software uMelt.
16 Temperatures displayed
represent the most frequent values from all the sequences tested.
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subjects were treated in accordance with the Declaration of
Helsinki. Samples were obtained either by anterior paracente-
sis (aqueous samples), posterior chamber paracentesis (undi-
luted vitreous samples), or during pars plana vitrectomy (both
undiluted vitreous and diluted vitreous washing samples).
Following collection, all specimens were immediately trans-
ported to the laboratory and stored at 208C. In total, 108
aqueous or vitreous fluid samples were included in this study.
Of those, 30 were collected from 18 patients with clinically
suspected viral or toxoplasma uveitis. Control specimens
included those collected from patients undergoing diagnosis
or treatment for conditions other than suspected uveitis (e.g.,
patients undergoing aqueous fluid removal as a routine part of
scleral buckle surgery for retinal detachment [21 specimens])
or patients with suspected bacterial or fungal endophthalmitis
(30 specimens from patients with culture-positive bacterial or
fungal endophthalmitis and 27 specimens from patients with
culture-negative but clinically diagnosed endophthalmitis)
(Supplementary Table S2). All specimens were tested in
triplicate in a masked fashion. Positive samples were
sequenced (Genewiz, South Plainfield, NJ, USA) for confirma-
tion of amplicon identities.
DNA Extraction
DNA extraction and purification was performed using a DNA
isolation kit (DNeasy Blood and Tissue Kit; Qiagen), following
the tissue protocol with few modifications. Chemical lysis was
achieved by mixing 100 lL primary aqueous or vitreous sample
with proteinase K, followed by the addition of a buffer (AL;
Qiagen) according to the manufacturer’s protocol. Purified DNA
was eluted from the silica membrane in 50 lL EB buffer (Qiagen).
RESULTS
Assay Optimization
Each of the five amplification targets—HSV-1, HSV-2, VZV,
CMV, and T. gondii—when tested individually, generated
products with characteristic melting curves possessing distinct
peak values by HRM analysis (Fig. 1). The identity of the
amplified product was verified by gel electrophoresis (Supple-
mentary Fig. S1) and then by DNA sequence. Experimentally
determined Tm values for each target were 79.18C for T. gondii,
81.78C for VZV, 85.78C for CMV, 90.38C for HSV-1, and 90.88C
for HSV-2 (Fig. 1; Table 1), in good agreement with predicted
values (consistently ~18C higher than experimentally deter-
mined for all targets). After confirming amplification of correct
products with distinct melting patterns, a single-tube multiplex
assay was optimized by combining all primer pairs in
concentrations ranging from 100 to 700 nM. Using purified
control DNA, primer concentrations of 100 nM for HSV1/2,
CMV, T. gondii, and 200 nM for VZV were found to be optimum
for detection of fluorescent signal over noise. In the multiplex
reaction, melting curve and Tm values were identical to those
determined in individual reactions. Conducted in this manner,
this assay is able to detect and identify any of the five targeted
pathogens in a single assay in 1 hour, 40 minutes.
Analytical Specificity
To ensure that each primer pair amplified only the intended
product and did not cross-react in multiplex, each pair was
tested in separate reactions for product generation using
control DNA for HSV-1, HSV-2, VZV, CMV, and T. gondii. To
determine whether the primers selected would be confounded
by DNA from other causes of intraocular infection, we also
tested them using DNA from rarer known causes of infectious
uveitis (T. pallidum and Mycobacterium tuberculosis) and
leading causes of endophthalmitis (S. epidermidis and S.
aureus), including microbes associated with chronic and low-
grade endophthalmitis that can mimic some uveitis symptoms
(P. acnes and C. albicans). Each set of primers was verified as
being specific for the intended target only.
Analytical Sensitivity
Serial 10-fold dilutions of DNA ranging from 1 3 105 genome
copies per microliter to one copy per microliter were tested in
order to determine the linearity and limits of detection, the
lowest concentration tested yielding consistent Ct values for
each triplicate sample (Fig. 2). Only dilutions showing a clear
and sharp Tm peak of the predicted value were considered
positive. For all the targets, the Ct values and Tm peaks were
FIGURE 1. Melting curve profiles for each target included in the assay following HRM analysis using SYBR GreenER. Tm values corresponding to
each peak are 79.18C for T. gondii, 81.78C for VZV, 85.78C for CMV, 90.38C for HSV-1, and 90.88C for HSV-2.
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clearly positive for reactions containing 20 genome copies,
except for T. gondii, for which the limit of detection was
estimated to be 200 genome copies per reaction.
Precision
To determine the random analytical error of our assay, we
calculated the intra- and interassay coefficient of variation by
measuring the Ct and Tm values of control DNA at or near the
limit of detection (200 copies per reaction) and well above (2
3 104 copies per reaction), using five technical replicates per
run. Interassay variability was determined by performing the
same test on 4 consecutive days (Supplementary Table S3). The
intra-assay variability of Ct measurements was 4% for all the
targets and concentrations, and interassay variation was 6%.
No Tm variability was seen. To approximate the range of Tm
variation that may stem from diversity in amplification
products generated from the diversity of natural isolates that
may occur in the patient population, melting curve predictions
were performed for DNA sequences corresponding to the
regions that would be amplified from a diverse collection of
strains collected across multiple countries. Sequences were
retrieved from National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov) and aligned using software
(Geneious v8; Biomatters, Inc., Newark, NJ, USA). The
accession numbers as well as the predicted Tm values for each
pathogen/strain amplicon are displayed in Supplementary
Table S1. For most of the targets included, none or very small
numbers of polymorphisms in the targeted regions were found.
These mutations would not be predicted to alter Tm to an
extent that would confound identification of the amplified
product (predicted variations ranged from 0.18C to 0.58C).
Clinical Validation
To clinically validate our assay, we first analyzed 30 samples
from 18 patients with clinically diagnosed viral or toxoplasma
uveitis (Table 2). Most of the patients were male (n ¼ 15,
83.3%), had a mean age of 53 years (621), and were
immunocompetent (n ¼ 10, 55.5%). On the basis of clinical
presentation, the patients were initially diagnosed with acute
retinal necrosis (ARN) (n ¼ 11), CMV retinitis (n ¼ 4),
toxoplasmosis chorioretinitis (n ¼ 2), and progressive outer
retinal necrosis (n ¼ 1). Using the newly developed multiplex
assay, we were able to unambiguously identify one of the
tested pathogens in 13 specimens collected from nine patients
(Table 3). The assay was effective in detecting pathogen DNA
in different specimen matrices, including aqueous humor (n¼
4), undiluted vitreous (n¼ 5), and diluted vitreous washings (n
¼4). The mean Ct values for the positive cases, calculated from
triplicates, varied from 19.4 to 27.7, with standard deviations
no higher than 60.7. Amplification of pathogen DNA from
positive clinical specimens generated Tm values corresponding
to HSV-2 (n¼ 5), VZV (n¼ 5), CMV (n¼ 2), and T. gondii (n¼
1). These identities were confirmed by sequencing the PCR
products and matching them to identities in GenBank using
BLAST software (available in the public domain, https://blast.
ncbi.nlm.nih.gov/Blast.cgi). As expected, Tm values for the
positive specimens did not vary measurably from controls.
In reviewing the cases included, the initial clinical diagnosis
was in agreement with PCR results for the majority of the cases
(Table 4). Of the nine patients from which positive samples
were collected, six had previously been diagnosed with ARN,
two with CMV retinitis, and one with progressive outer retinal
necrosis (PORN; which is typically caused by herpesviruses or
CMV retinitis), based on clinical presentations. PCR showed
specific pathogen identities consistent with all of these
diagnoses, except for the one PORN patient specimen in
which toxoplasma DNA was identified. T. gondii infection may
cause symptoms shared by PORN. Rather than antiviral
treatment, therapy specific for toxoplasma infection would
be expected to be of greater benefit in such cases.
Nine other specimens derived from patients suspected of
having viral retinitis or ocular toxoplasmosis yielded negative
FIGURE 2. Standard curves obtained by testing serial 10-log dilutions ranging from 23105 copies to 2 copies per reaction. Calculations of efficiency
(E) for each reaction are shown. Efficiency was calculated from the slope given by regression analysis using the formula E ¼ 10(1/slope)  1.
Coefficients of correlation (R2) are also shown.
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PCR results. From the two patients with symptoms consistent
with inflammation of toxoplasmic etiology, one had a single
aqueous humor sample collected and the other had already
been treated with trimethroprim-sulfamethoxazole for 1 week
at the time of collection. Toxoplasma DNA may be more
difficult to detect in aqueous humor than that of other
organisms.13 For the remaining suspected viral retinitis cases,
two were being treated with antiviral medications at the time
of sampling, and there were no known factors for the
remaining five samples that may have contributed to PCR
negativity (Table 5).
To determine the clinical specificity and complete the
clinical validation of our assay, we collected and tested control
intraocular fluids from noninfected eyes (n¼ 21) and bacterial
and fungal endophthalmitis cases that were either positive (n¼
30) or negative by culture (n ¼ 27). Eight yielded a Ct value
that crossed the threshold for positivity, but only one generated
a well-defined Tm peak (86.78C), which was not close (within
0.58C) to any of the pathogens for which the test was designed.
Sequencing of this sample resulted in a mixed trace file that did
not give an interpretable sequence, suggesting it was a mixture
of yet unknown amplification products. As this atypical Tm
value fell outside the values used for pathogen identification or
predicted for any known variants, it was dismissed as an
artifact of amplification. These artifacts were not seen when
the samples were tested individually using each primer in
singleplex reactions, excluding the possibility of polymicrobial
infection. None of the control samples yielded a positive result
for any of the uveitis pathogens included in our assay
(Supplementary Table S2).
DISCUSSION
Uveitis is a sight-threatening inflammation of the uveal tract
that is caused by a variety of infectious agents and noninfec-
tious causes. Diagnosing an etiology for this disease based on
clinical findings alone is often challenging owing to confound-
ing and overlapping features. PCR-based assays have been used
to discriminate infectious from noninfectious causes of
intraocular inflammation and for identification of the causative
agent.9,12,13,20–25 However, most of these tests are singleplex
reactions performed by traditional PCR methods that rely on
post-PCR handling for detection and identification, increasing
turnaround time and risk of carryover contamination. The
multiplex assay described here was designed to detect the
most common uveitis pathogens using real-time PCR technol-
ogy. It uses a single reaction that allows DNA amplification and
fluorescence-based amplicon identification. Importantly, rapid
detection of leading uveitis pathogens in a multiplex format
was possible without compromising test sensitivity. The limits
of detection of our multiplex assay were as high or higher than
reported tests for herpesviruses or T. gondii detection from
intraocular fluids and other body sites.26,27 By exploring the
advantages of HRM analysis, we were able to develop a
sensitive assay for simultaneous detection and precise identi-
fication of HSV-1, HSV-2, VZV, CMV, and T. gondii directly from
intraocular fluids in less than 2 hours. This opens the door to
rapid initiation of effective therapy.
Although TaqMan-based real-time PCR assays are extensively
used for molecular diagnostics and have been described for the
detection of herpesviruses from intraocular fluids,28 the
multiplexing capability of this method is constrained by the
availability of different filters to detect each fluorescent agent.
Monitoring DNA amplification by the use of a dedicated DNA-
intercalating fluorophore may permit the addition or replace-
ment of targets according to specific clinical needs, as long as
the new target displays a melting profile distinct enough from
the existing targets included in the panel. Thus, the number or
TABLE 2. Characteristics of Patients (n¼18) With Clinical Diagnosis of
Infectious Uveitis Included in the Validation of the Multiplex Assay
Sex
Male (%) 15 (83.3)
Female (%) 3 (16.7)
Age, y
Mean (StDev) 53 (621)
Range 14–84
Immune status
Immunocompetent (%) 10 (55.5)
Immunosuppressed (%) 3 (16.7)
Others/unknown (%) 5 (27.8)
Initial clinical diagnosis
ARN (%) 11 (61.1)
CMV retinitis (%) 4 (22.2)
Toxoplasmosis chorioretinitis (%) 2 (11.1)
PORN (%) 1 (5.6)
PORN, progressive outer retinal necrosis.
TABLE 3. Multiplex PCR and Sequencing Results for the Positive Clinical Specimens
Patient
No. Specimen (Eye)
Multiplex PCR Assay Sequencing Identification
Mean Ct
Value (StDev)
Tm
Value
Tm
Identity Best Hit (Accession Numbers)
Identity,
%
Query
Coverage, % E-Value
Product
Size, bp
1 Vitreous (OS) 27.68 (0.12) 90.8 HSV2 Human herpesvirus 2 (KU310665) 99 100 1e-112 235
2 Vitreous (OS) 19.44 (0.57) 90.8 HSV2 Human herpesvirus 2 (KU310666) 100 99 9e-115 235
VW (OS) 20.11 (0.19) 90.8 HSV2 Human herpesvirus 2 (KU310666) 100 100 3e-115 235
3 Aqueous (OD) 24.27 (018) 90.8 HSV2 Human herpesvirus 2 (KU310665) 100 100 3e-115 235
Aqueous (OS) 26.76 (0.08) 90.8 HSV2 Human herpesvirus 2 (KU310665) 100 100 3e-114 233
4 Vitreous (OD) 24.35 (0.50) 81.7 VZV Human herpesvirus 3 (KU926322) 100 100 8e-109 223
VW (OD) 26.2 (0.71) 81.7 VZV Human herpesvirus 3 (KU926322) 100 100 8e-109 223
5 Vitreous (OS) 27.50 (0.33) 81.7 VZV Human herpesvirus 3 (KX262866) 100 100 8e-109 223
VW (OS) 27.19 (0.68) 81.7 VZV Human herpesvirus 3 (KX262866) 100 100 8e-109 223
6 Aqueous (OD) 23.20 (0.15) 81.7 VZV Human herpesvirus 3 (KX262866) 100 99 4e-107 222
7 VW (OS) 27.37 (0.29) 85.7 CMV Human herpesvirus 5 (AH002793) 100 100 6e-104 214
8 Aqueous (OD) 22.38 (0.23) 85.7 CMV Human herpesvirus 5 (AH002793) 100 100 6e-104 214
9 Vitreous (OD) 26.86 (0.22) 79.1 T. gondii T. gondii (LN714499)* 100 100 5e-50 114
VW, vitreous washing; Ct, cycles threshold; Tm, melting temperature; OS, left eye; OD, right eye.
* T. gondii sequence was searched against the whole genome shot gun contigs database.
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nature of targets may be modified independently on the
number of filters in the available PCR systems. SYBR GreenER
is also more economical than most hydrolysis probes.
An unexplored theoretical challenge for the detection
method described here would be in deconvoluting the signal
that could result from amplification of two different targets in
the same sample. The occurrence of multiple known uveitis
pathogens in a sample is rare,9 and an uninterpretable result
could be further analyzed in demultiplexed reactions using the
same primers.
Validation of the assay on intraocular fluids collected from
suspected cases of viral or toxoplasmic uveitis demonstrated
an overall clinical sensitivity (9 patients out of 18, 50%),
comparable to that of previous studies.5,9,12 The etiology of
infectious uveitis is not completely understood, and rapid
positive identification of patients with known common causes
will facilitate the discovery of new pathogens in others.
Most of the PCR-positive cases presented with ARN, a
rapidly progressive, fulminant, necrotizing viral retinitis that
mainly affects immunocompetent patients, which is more
often caused by VZV than by HSV-1 and -2 and is rarely caused
by CMV.5,7,29 The distribution of causative agents for the PCR-
positive cases analyzed here broadly reflected this trend. HSV-2
and VZV were the most common pathogens identified,
followed by CMV. A predominance of HSV-2 over HSV-1 in
ARN cases has been reported29,30 and appears to be age
dependent. Uveitis patients 25 years old or younger are more
frequently infected by HSV-2, even without a clearly defined
history of neonatal infection, whereas HSV-1 is more common-
ly found in uveitis specimens from older patients. All HSV-2–
positive patient specimens (n ¼ 3) analyzed here were from
males: two young, immunocompetent adults (23 and 26 years
old) and one elderly adult (80 years old). HSV-2 primary
infection usually affects the genital tract and perigenital and
anal skin areas. Thus, maternal transmission may occur
congenitally or at the time of delivery.31 It has been
hypothesized that the enrichment of HSV-2 retinitis in young
patients without history of neonatal infection could be
associated to the reactivation of a well-established latent
infection in the cranial nerve (with subsequent spreading to
the retina) that was perinatally acquired, and not previously
diagnosed.32
The parasite T. gondii was detected in only one case in our
series, from a patient initially suspected of having PORN, a
disease commonly caused by herpesviruses. This atypical
ocular toxoplasmosis presentation in an immunosuppressed
patient highlights the potential clinical impact of molecular
testing for optimal management of infectious uveitis. Two
other patients presenting with symptoms consistent with T.
gondii infection were negative by PCR. For one patient only an
aqueous humor specimen was available. The other was under
treatment (1 week of trimethoprim-sulfamethoxazole) for
toxoplasmosis at the time of collection, which may have
impaired our ability to detect toxoplasma DNA from the
specimens.
Laboratory diagnosis of posterior toxoplasmic uveitis is
often challenging and may require the combination of PCR
testing with intraocular antibody measurement (Goldmann-
Witmer coefficient [GWC] analysis) as complementary tests.
Multiple existing tests have been found to improve the rate of
patients that have a final etiologic diagnosis of toxoplasmic
retinitis, and both traditional PCR and GWC are challenged by
TABLE 5. Characteristics of the Nine Patients With Clinical Diagnosis of Infectious Uveitis and Negative PCR Results
Patient
No. Age Sex Immune Status Clinical Diagnosis
Therapy at Time
of Sampling
Specimen
(Eye)
PCR
Result
10 65 M Immunocompetent Toxoplasmosis chorioretinitis Trimethoprim-sulfamethoxazole Vitreous (OD) Negative
VW (OD) Negative
VW (OS) Negative
11 28 M Immunocompetent Toxoplasmosis chorioretinitis None Aqueous (OD) Negative
12 84 F Unknown ARN None Aqueous (OD) Negative
13 36 M Immunocompetent ARN None Vitreous (OD) Negative
14 57 F History of lung transplant CMV retinitis None Vitreous (OS) Negative
15 67 M Immunocompetent ARN Valganciclovir Vitreous (OD) Negative
16 61 M Immunocompetent ARN None Vitreous (OD) Negative
17 51 F Immunosuppressed CMV retinitis Valganciclovir Aqueous (OS) Negative
18 14 M History of lymphoma ARN None VW (OD) Negative
Vitreous (OD) Negative
Vitreous (OD) Negative
VW, vitreous washing; M, male; F, female; ARN, acute retinal necrosis; OS, left eye; OD, right eye.
TABLE 4. Characteristics of the Nine Patients With Clinical Diagnosis of Infectious Uveitis and Positive PCR Results
Patient No. Age Sex Immune Status Therapy* Clinical Diagnosis PCR Result
1 23 M Immunocompetent Unknown ARN HSV2
2 26 M Immunocompetent Intravenous acyclovir and antibiotics ARN HSV2
3 80 M Unknown Intravenous acyclovir ARN HSV2
4 61 M Immunocompetent Intravitreal foscarnet ARN VZV
5 64 M Immunocompetent Intravitreal foscarnet and valganciclovir ARN VZV
6 82 M Immunocompetent Unknown ARN VZV
7 49 M Immunosuppressed Valganciclovir CMV retinitis CMV
8 76 M Unknown Unknown CMV retinitis CMV
9 44 M Immunosuppressed Antiviral therapy PORN T. gondii
M, male; ARN, acute retinal necrosis; PORN, progressive outer retinal necrosis.
* Therapy the patient was receiving at the sampling time.
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sensitivity issues associated with the timing of specimen
collection in the course of the disease. Historically, the use of
PCR by itself for the diagnosis of ocular toxoplasmosis has
lower or similar sensitivity to that of local antibody detec-
tion.22,33–35 This may account for the relatively low number of
patients with uveitis found positive for T. gondii (n¼ 1) among
our sample set.
Although we validated this assay with clinical samples
positive for most of the targets included, a specimen positive
for HSV-1 uveitis was not found in our population. Neverthe-
less, the assay developed here detects HSV-1 control DNA with
limits of detection similar to the other targets, and we would
predict finding such samples in a larger set.
In summary, the multiplex assay developed here provides
sensitive and reliable qualitative detection and identification of
the common uveitis-associated herpesviruses and T. gondii,
directly from intraocular fluids in a single closed-tube reaction.
Moreover, with all reactions being performed in a single tube in
a single instrument in under 2 hours, results can be generated
while a patient is still available. Thus, this qualitative assay may
represent a useful laboratory test for identification of
pathogens in clinically suspected cases of uveitis, with the
potential for reducing vision lost due to delays in the onset of
effective therapy.
Acknowledgments
Note: A recent report appeared describing multiplex amplification
of some of the pathogens, without the high resolution melting
detection and validation used here, and showed consistent
findings, providing further support for this approach.36
The authors thank Jenna Wurster for technical support throughout
the course of this work. They also thank the physicians of the
Retina and Uveitis Services of the Massachusetts Eye and Ear
Infirmary, Harvard Medical School, Boston, MA, USA.
Supported in part by an NIH grant (EY024285), by the Harvard-
wide Program on Antibiotic Resistance (AI083214), and by a grant
from the Coordenac¸a˜o de Aperfeic¸oamento de Pessoal de Nı´vel
Superior, Brazil (CAPES #9775-13-7) (PJMB). Funding agencies had
no role in study design, data analysis, decision to publish, or
preparation of the manuscript.
Disclosure: P.J.M. Bispo, None; S. Davoudi, None; M.L. Sahm,
None; A. Ren, None; J. Miller, None; J. Romano, None; L.
Sobrin, None; M.S. Gilmore, None
References
1. Acharya NR, Tham VM, Esterberg E, et al. Incidence and
prevalence of uveitis: results from the Pacific Ocular
Inflammation Study. JAMA Ophthalmol. 2013;131:1405–
1412.
2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in
Northern California: the Northern California Epidemiology of
Uveitis Study. Ophthalmology. 2004;111:491–500; discussion
500.
3. Suttorp-Schulten MS, Rothova A. The possible impact of
uveitis in blindness: a literature survey. Br J Ophthalmol.
1996;80:844–848.
4. Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral
patterns of uveitis in a tertiary eye care center. Arch
Ophthalmol. 1996;114:593–599.
5. Lau CH, Missotten T, Salzmann J, Lightman SL. Acute retinal
necrosis features, management, and outcomes. Ophthalmol-
ogy. 2007;114:756–762.
6. Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk
factors for visual acuity loss among patients with AIDS and
cytomegalovirus retinitis in the era of highly active antiretro-
viral therapy. Ophthalmology. 2006;113:1432–1440.
7. Tran TH, Rozenberg F, Cassoux N, Rao NA, LeHoang P,
Bodaghi B. Polymerase chain reaction analysis of aqueous
humour samples in necrotising retinitis. Br J Ophthalmol.
2003;87:79–83.
8. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV,
Rimmer TG; for the UCLA Community-Based Uveitis Study
Group. Causes of uveitis in the general practice of ophthal-
mology. Am J Ophthalmol. 1996;121:35–46.
9. Knox CM, Chandler D, Short GA, Margolis TP. Polymerase
chain reaction-based assays of vitreous samples for the
diagnosis of viral retinitis. Use in diagnostic dilemmas.
Ophthalmology. 1998;105:37–44; discussion 44–45.
10. Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic
approaches to severe, atypical toxoplasmosis mimicking
acute retinal necrosis. Ophthalmology. 2004;111:716–725.
11. Rothova A, Ooijman F, Kerkhoff F, Van Der Lelij A, Lokhorst
HM. Uveitis masquerade syndromes. Ophthalmology. 2001;
108:386–399.
12. Harper TW, Miller D, Schiffman JC, Davis JL. Polymerase chain
reaction analysis of aqueous and vitreous specimens in the
diagnosis of posterior segment infectious uveitis. Am J
Ophthalmol. 2009;147:140–147.e2.
13. Rothova A, de Boer JH, Ten Dam-van Loon NH, et al.
Usefulness of aqueous humor analysis for the diagnosis of
posterior uveitis. Ophthalmology. 2008;115:306–311.
14. Whitcombe D, Newton CR, Little S. Advances in approaches
to DNA-based diagnostics. Curr Opin Biotechnol. 1998;9:
602–608.
15. Tong SY, Giffard PM. Microbiological applications of high-
resolution melting analysis. J Clin Microbiol. 2012;50:3418–
3421.
16. Dwight Z, Palais R, Wittwer CT. uMELT: prediction of high-
resolution melting curves and dynamic melting profiles of
PCR products in a rich web application. Bioinformatics.
2011;27:1019–1020.
17. Blake RD, Delcourt SG. Thermal stability of DNA. Nucleic
Acids Res. 1998;26:3323–3332.
18. Vallone PM, Butler JM. AutoDimer: a screening tool for
primer-dimer and hairpin structures. Biotechniques. 2004;37:
226–231.
19. Bispo PJ, de Melo GB, Hofling-Lima AL, Pignatari AC.
Detection and gram discrimination of bacterial pathogens
from aqueous and vitreous humor using real-time PCR assays.
Invest Ophthalmol Vis Sci. 2011;52:873–881.
20. Cunningham ET Jr, Short GA, Irvine AR, Duker JS, Margolis TP.
Acquired immunodeficiency syndrome–associated herpes
simplex virus retinitis. Clinical description and use of a
polymerase chain reaction–based assay as a diagnostic tool.
Arch Ophthalmol. 1996;114:834–840.
21. de Boer JH, Verhagen C, Bruinenberg M, et al. Serologic and
polymerase chain reaction analysis of intraocular fluids in the
diagnosis of infectious uveitis. Am J Ophthalmol. 1996;121:
650–658.
22. De Groot-Mijnes JD, Rothova A, Van Loon AM, et al.
Polymerase chain reaction and Goldmann-Witmer coefficient
analysis are complimentary for the diagnosis of infectious
uveitis. Am J Ophthalmol. 2006;141:313–318.
23. Fox GM, Crouse CA, Chuang EL, et al. Detection of
herpesvirus DNA in vitreous and aqueous specimens by the
polymerase chain reaction. Arch Ophthalmol. 1991;109:266–
271.
24. McCann JD, Margolis TP, Wong MG, et al. A sensitive and
specific polymerase chain reaction-based assay for the
diagnosis of cytomegalovirus retinitis. Am J Ophthalmol.
1995;120:219–226.
25. Short GA, Margolis TP, Kuppermann BD, Irvine AR, Martin DF,
Chandler D. A polymerase chain reaction-based assay for
diagnosing varicella-zoster virus retinitis in patients with
Molecular Diagnosis of Infectious Uveitis IOVS j January 2018 j Vol. 59 j No. 1 j 588
acquired immunodeficiency syndrome. Am J Ophthalmol.
1997;123:157–164.
26. Dabil H, Boley ML, Schmitz TM, Van Gelder RN. Validation of a
diagnostic multiplex polymerase chain reaction assay for
infectious posterior uveitis. Arch Ophthalmol. 2001;119:
1315–1322.
27. Stranska R, Schuurman R, de Vos M, van Loon AM. Routine
use of a highly automated and internally controlled real-time
PCR assay for the diagnosis of herpes simplex and varicella-
zoster virus infections. J Clin Virol. 2004;30:39–44.
28. Sugita S, Shimizu N, Watanabe K, et al. Use of multiplex PCR
and real-time PCR to detect human herpes virus genome in
ocular fluids of patients with uveitis. Br J Ophthalmol. 2008;
92:928–932.
29. Ganatra JB, Chandler D, Santos C, Kuppermann B, Margolis
TP. Viral causes of the acute retinal necrosis syndrome. Am J
Ophthalmol. 2000;129:166–172.
30. Van Gelder RN, Willig JL, Holland GN, Kaplan HJ. Herpes
simplex virus type 2 as a cause of acute retinal necrosis
syndrome in young patients. Ophthalmology. 2001;108:869–
876.
31. Whitley R, Kimberlin DW, Prober CG. Pathogenesis and
disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, et al.,
eds. Human Herpesviruses: Biology, Therapy, and Immuno-
prophylaxis. Cambridge, UK: Cambridge University Press;
2007.
32. Grose C. Acute retinal necrosis caused by herpes simplex
virus type 2 in children: reactivation of an undiagnosed latent
neonatal herpes infection. Semin Pediatr Neurol. 2012;19:
115–118.
33. Garweg JG, Jacquier P, Boehnke M. Early aqueous humor
analysis in patients with human ocular toxoplasmosis. J Clin
Microbiol. 2000;38:996–1001.
34. Talabani H, Asseraf M, Yera H, et al. Contributions of
immunoblotting, real-time PCR, and the Goldmann-Witmer
coefficient to diagnosis of atypical toxoplasmic retinocho-
roiditis. J Clin Microbiol. 2009;47:2131–2135.
35. Villard O, Filisetti D, Roch-Deries F, Garweg J, Flament J,
Candolfi E. Comparison of enzyme-linked immunosorbent
assay, immunoblotting, and PCR for diagnosis of toxoplasmic
chorioretinitis. J Clin Microbiol. 2003;41:3537–3541.
36. Kumar A, Singh MP, Bansal R, Gupta A, Ram J, Ratho RK.
Development and evaluation of multiplex real-time PCR for
diagnosis of HSV-1, VZV, CMV, and Toxoplasma gondii in
patients with infectious uveitis. Diagn Microbiol Infect Dis.
2017;89:191–196.
Molecular Diagnosis of Infectious Uveitis IOVS j January 2018 j Vol. 59 j No. 1 j 589
